Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2018-11-12

FDA Approved: OCREVUS — Supplemental Application (Genentech, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for Ocrevus (ocrelizumab) submitted by Genentech, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Ocrevus (ocrelizumab)

Snippet

SUPPL AP for OCREVUS (OCRELIZUMAB)